Can a simple test predict immunotherapy outcomes for pancreatic cancer?
NCT ID NCT07271823
First seen Jan 06, 2026 · Last updated Jun 20, 2026 · Updated 22 times
Summary
This study aims to develop a way to predict which patients with advanced pancreatic cancer will respond to immunotherapy. Researchers will collect tumor tissue, blood, and stool samples from 100 participants before and during treatment. By analyzing these samples, they hope to create a model that forecasts treatment response, potentially personalizing cancer care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER NON-RESECTABLE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Zhejiang, Hangzhou, 310022, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which pancreatic cancer patients will benefit from immunotherapy, leading to more personalized and effective treatment plans.
What could go wrong
This is an early observational study, not a treatment trial. The predictive model may not be accurate enough for clinical use, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.